Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
A Multicenter, Open-Label, Two-Stage, Phase II Study Of PS-341 (LDP-341, NSC # 681239) In Patients With Unresectable Or Metastatic Gastric Adenocarcinoma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.
研究概览
详细说明
OBJECTIVES:
Primary
- Determine the efficacy of bortezomib in patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Secondary
- Determine the toxicity of this drug in these patients.
- Determine possible predictors of response to this drug, using pretreatment tumor immunohistochemistry, in these patients.
OUTLINE: This is an open-label, nonrandomized, multicenter study.
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year.
PROJECTED ACCRUAL: A total of 15-33 patients will be accrued for this study within 5-12 months.
研究类型
阶段
- 阶段2
联系人和位置
学习地点
-
-
Illinois
-
Chicago、Illinois、美国、60637-1470
- University of Chicago Cancer Research Center
-
-
New York
-
Jamaica、New York、美国、11432
- Queens Cancer Center of Queens Hospital
-
New York、New York、美国、10021
- Memorial Sloan-Kettering Cancer Center
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792-3236
- University of Wisconsin Comprehensive Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
- Siewert's class II or III disease
Measurable disease
- At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
- No history of known or active brain metastases or primary brain tumors
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Karnofsky 60-100% OR
- ECOG 0-2
Life expectancy
- Not specified
Hematopoietic
- WBC at least 3,000/mm^3
- Absolute neutrophil count at least 1,000/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
- Bilirubin no greater than 1.5 mg/dL
- AST and ALT no greater than 3 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
Renal
- Creatinine no greater than 1.5 mg/dL
Cardiovascular
- No prior cerebrovascular event
- No prior orthostatic hypotension
- No myocardial infarction within the past 6 months
- No peripheral vascular disease requiring surgical management
- No evidence of acute ischemia or significant conduction abnormality by EKG
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for at least 2 months after study participation
- No evidence of peripheral neuropathy
- No prior allergic reaction attributed to compounds of similar chemical or biological composition to bortezomib
- No other malignancy within the past 3 years except basal cell skin cancer, carcinoma in situ of the cervix, or adequately treated nonmetastatic prostate cancer
- No ongoing or active infection
- No psychiatric illness or social situation that would preclude study participation
- No other concurrent uncontrolled illness that would preclude study participation
- No other medical condition or reason that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
- More than 3 weeks since prior immunotherapy
- No concurrent biological or immunological agents
Chemotherapy
- No more than 1 prior chemotherapy regimen (including adjuvant chemotherapy)
- More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
- No concurrent chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- More than 3 weeks since prior radiotherapy
- No concurrent radiotherapy
Surgery
- Not specified
Other
- Recovered from all prior therapy
- No other concurrent investigational agents
- No other concurrent anticancer agent or therapy
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 屏蔽:无(打开标签)
合作者和调查者
调查人员
- 首席研究员:Manish A. Shah, MD、Memorial Sloan Kettering Cancer Center
- 首席研究员:Gary K. Schwartz, MD、Memorial Sloan Kettering Cancer Center
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.